DOI QR코드

DOI QR Code

국내 다제내성 및 광범위내성결핵의 최근 현황

The Recent Status of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea

  • 김선영 (울산대학교 의과대학 서울아산병원 호흡기내과학교실) ;
  • 김희진 (결핵연구원) ;
  • 김창기 (결핵연구원) ;
  • 윤혜령 (서울의과학연구소) ;
  • 배혜경 (녹십자의료재단) ;
  • 이선화 (네오딘의학연구소) ;
  • 성낙문 (국립마산병원) ;
  • 김대연 (국립목포병원) ;
  • 이강영 (서북병원) ;
  • 조영수 (서북병원) ;
  • 이상도 (울산대학교 의과대학 서울아산병원 호흡기내과학교실) ;
  • 김우성 (울산대학교 의과대학 서울아산병원 호흡기내과학교실) ;
  • 김동순 (울산대학교 의과대학 서울아산병원 호흡기내과학교실) ;
  • 심태선 (울산대학교 의과대학 서울아산병원 호흡기내과학교실)
  • Kim, Sun-Young (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Hee-Jin (Korean Institute of Tuberculosis) ;
  • Kim, Chang-Ki (Korean Institute of Tuberculosis) ;
  • Yoon, Hye-Ryung (Seoul Medical Science Institute) ;
  • Bae, Hye-Gyung (Green Cross Reference Laboratory) ;
  • Lee, Sun-Hwa (Neodin Medical Institute) ;
  • Sung, Nack-Moon (National Masan Hospital) ;
  • Kim, Dae-Yeon (National Mokpo Hospital) ;
  • Lee, Gang-Young (Seobuk Hospital) ;
  • Cho, Young-Soo (Seobuk Hospital) ;
  • Lee, Sang-Do (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Woo-Sung (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Dong-Soon (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Shim, Tae-Sun (Division of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2010.01.28
  • 심사 : 2010.02.17
  • 발행 : 2010.03.30

초록

Background: The increasing incidence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has become a serious worldwide problem. However, there is insufficient data regarding the current status of MDR-TB and XDR-TB in Korea. This study examined the recent status of MDR- and XDR-TB using the data from 7 laboratories, in which almost all drug susceptibility tests (DST) for Mycobacterium tuberculosis were performed. Methods: The patients' identification data and DST results were collected from all 7 laboratories from 2001 to 2006 and the number of patients with MDR-TB and XDR-TB were calculated. Results: The number of DSTs was 140,638 for 6 years with an increasing incidence each year (p<0.001). The number of DST with MDR results was 18,510 and personal identifying information was obtained in 16,640 (89.9%) tests. The number of MDR-TB patients from 2001 to 2006 was 2,329, 2,496, 2,374, 2,300, 2,354, and 2,178, respectively, when counting the duplications in a year as one patient. The number of MDR-TB patients when counting the duplications in 6 years as one patient was 2,281, 1,977, 1,620, 1,446, 1,512, and 1,373, respectively. When the same method was adopted, the number of XDR-TB patients was 191, 238, 282, 260, 272, and 264, respectively, and 189, 150, 130, 90, 122, and 110 patients, respectively. Conclusion: Despite the national efforts to control TB, there are still a large number of MDR- and XDR-TB patients in Korea.

키워드

참고문헌

  1. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997: World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med 1998;338:1641-9. https://doi.org/10.1056/NEJM199806043382301
  2. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80. https://doi.org/10.1016/S0140-6736(06)69573-1
  3. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, Ziazarifi AH, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drugresistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009;136:420-5. https://doi.org/10.1378/chest.08-2427
  4. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis 2007;11:571-6.
  5. Bae GH. National tuberculosis control program in Korea: actions for TB elimination. Commun Dis Mon Rep 2006;17:1-10.
  6. Jeon D, Shin D, Kang H, Sung N, Kweon K, Shin E, et al. Trend of multidrug and extensively drug resistant tuberculosis in a tuberculosis referral hospital, 2001-2005. Tuberc Respir Dis 2008;64:187-93. https://doi.org/10.4046/trd.2008.64.3.187
  7. Kim BJ, Lee IH, Lee DH, Bai GH, Kong SJ, Lee SH, et al. The current status of multidrug-resistant tuberculosis in Korea. Tuberc Respir Dis 2006;60:404-11. https://doi.org/10.4046/trd.2006.60.4.404
  8. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec 2006;81:408.
  9. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009;373:1861-73. https://doi.org/10.1016/S0140-6736(09)60331-7
  10. World Health Organization. Global map and information on XDR-TB: countries that had reported at least one XDR-TB case by September 2009 [internet]. Geneva: World Health Organization; 2009 [cited 2009 Dec 20]. Available from: http://www.who.int/tb/challenges/xdr/xdr_map_sep09.pdf.
  11. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs: worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-5.
  12. Kim DH, Kim HJ, Park SK, Kong SJ, Kim YS, Kim TH, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008;178:1075-82. https://doi.org/10.1164/rccm.200801-132OC

피인용 문헌

  1. 일개 부산지역 3차 병원에서 관찰한 다제내성 결핵의 실태, 2005~2009 vol.71, pp.2, 2010, https://doi.org/10.4046/trd.2011.71.2.120
  2. The efficacy of rifabutin for rifabutin-susceptible, multidrug-resistant tuberculosis vol.107, pp.2, 2010, https://doi.org/10.1016/j.rmed.2012.10.021